已收盤 08-07 16:00:00 美东时间
+0.010
+0.05%
Cantor Fitzgerald analyst Josh Schimmer maintains Trevi Therapeutics (NASDAQ:TRVI) with a Overweight and raises the price target from $25 to $30.
08-07 20:09
Trevi Therapeutics(TRVI)2026年第二季度净亏损1,779.7万美元,每股亏损0.11美元,研发费用升至1,515.2万美元;融资后现金及有价证券达3.189亿美元。
08-07 01:42
Trevi Therapeutics, Inc. will host a conference call and webcast on August 6, 2026, at 4:30 p.m. ET, to discuss its financial results and corporate updates for the quarter ended June 30, 2026. The company is developing Haduvio™ (oral nalbuphine ER) for chronic cough treatment in IPF, non-IPF ILD, and RCC patients. Haduvio has shown significant reduction in cough frequency and improved patient outcomes. No FDA-approved therapies exist for these co...
07-30 20:05
今日重点评级关注:HC Wainwright & Co.:维持Greenwich LifeSciences"买入"评级,目标价从50美元升至69美元;高盛:维持Taysha Gene Therapies"买入"评级,目标价从11美元升至13美元
07-22 11:35
今日重点评级关注:Needham:维持Immuneering"买入"评级,目标价从11美元升至18美元;富瑞:维持塞德斯医疗"买入"评级,目标价从90美元升至100美元
07-21 11:36
After GSK (GSK) announced it would discontinue a chronic cough therapy following a late-stage trial failure, Trevi Therapeutics (TRVI), which is advancing a rival candidate, traded higher to reach an ...
07-18 02:04
U.S. stocks were lower, with the Nasdaq Composite falling around 400 points on Friday. Shares of ManpowerGroup Inc (NYSE:MAN) rose sharply after the company reported upbeat second-quarter results and issued third-quarter earnings guidance above expectations. Adjusted earnings were 99 cents per share...
07-17 22:09
Trevi Therapeutics, Inc. announced that senior management will attend several key events in June and July 2026, including the BIO International Convention, Leerink Partners Therapeutics Forum, and ERS Cough Conference. The company is developing Haduvio™, an investigational therapy for chronic cough in patients with IPF, non-IPF ILD, and refractory chronic cough (RCC). Haduvio™ has shown statistically significant reductions in cough frequency in c...
06-17 11:30
今日重点评级关注:Oppenheimer:维持Protara Therapeutics"跑赢大市"评级,目标价从25美元升至28美元;Piper Sandler:维持Bright Minds Biosciences"超配"评级,目标价从190美元升至220美元
05-21 12:05